These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 978409)

  • 1. Bioavailability of 11 sulfisoxazole products in humans.
    Slywka GW; Melikian AP; Straughn AB; Whyatt PL; Meyer MC
    J Pharm Sci; 1976 Oct; 65(10):1494-8. PubMed ID: 978409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the physiological availability and metabolism of sulfonamides. II. Sulfisoxazole.
    Van Petten GR; Becking GC; Withey RJ; Lettau HF
    J Clin Pharmacol New Drugs; 1971; 11(1):35-41. PubMed ID: 4926394
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioavailability of propylthiouracil in humans.
    Ringhand HP; Ritschel WA; Meyer MC; Straughn AB; Cabana BE
    J Pharm Sci; 1983 Dec; 72(12):1409-12. PubMed ID: 6663476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative dissolution performance of internationally available piroxicam products.
    Barone JA; Lordi NG; Byerly WG; Colaizzi JL
    Drug Intell Clin Pharm; 1988 Jan; 22(1):35-40. PubMed ID: 3349918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo-in vitro correlations with a commercial dissolution simulator II: papaverine, phenytoin, and sulfisoxazole.
    Yau MK; Meyer MC
    J Pharm Sci; 1983 Jun; 72(6):681-6. PubMed ID: 6875829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dissolution behaviors and gastrointestinal absorption of sulfisoxazole in sulfisoxazole-polyvinylpyrrolidone coprecipitate (author's transl)].
    Sekikawa H; Nakano M; Arita T
    Yakugaku Zasshi; 1978 Jan; 98(1):62-6. PubMed ID: 641703
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro and in vivo characteristics of some commercial phenobarbital tablets.
    Sylvestri MF; Ueda CT
    Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):492-7. PubMed ID: 528095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PH-dependent drug release from certain commercial tablets.
    Sutton JE; Lach JL; Wagner RS
    Am J Hosp Pharm; 1977 Dec; 34(12):1323-6. PubMed ID: 23005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bioinequivalence of carbamazepine tablets with a history of clinical failures.
    Meyer MC; Straughn AB; Jarvi EJ; Wood GC; Pelsor FR; Shah VP
    Pharm Res; 1992 Dec; 9(12):1612-6. PubMed ID: 1488405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of sulfisoxazole in young and elderly subjects.
    Boisvert A; Barbeau G; Bélanger PM
    Gerontology; 1984; 30(2):125-31. PubMed ID: 6706125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lipids on bioavailability of sulfisoxazole acetyl, dicumarol, and griseofulvin in rats.
    Bloedow DC; Hayton WL
    J Pharm Sci; 1976 Mar; 65(3):328-34. PubMed ID: 57233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of pharmaceutical quality of furosemide tablets from multinational markets.
    Qureshi SA; McGilveray IJ
    Drug Dev Ind Pharm; 1998 Nov; 24(11):995-1005. PubMed ID: 9876554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro-in vivo correlation and dissolution studies with oral theophylline dosage forms.
    el-Yazigi A; Sawchuk RJ
    J Pharm Sci; 1985 Feb; 74(2):161-4. PubMed ID: 3989685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and dissolution parameters of seven lithium carbonate products.
    Needham TE; Javid P; Brown W
    J Pharm Sci; 1979 Aug; 68(8):952-4. PubMed ID: 480173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal transport mechanisms for the excretion of sulfisoxazole.
    Cohen M; Pocelinko R
    J Pharmacol Exp Ther; 1973 Jun; 185(3):703-12. PubMed ID: 4712659
    [No Abstract]   [Full Text] [Related]  

  • 16. Simultaneous determination of N(1)-acetyl sulfisoxazole and its metabolites, and relative bioavailability compare to sulfisoxazole in rats.
    Kim E; Kang W
    J Pharm Biomed Anal; 2016 Sep; 129():117-120. PubMed ID: 27423008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative bioavailability of erythromycin-sulfisoxazole combinations.
    Desante KA; Ryan CF; Wallen S; Heath EC
    Pediatr Infect Dis; 1986; 5(1):141-6. PubMed ID: 3945569
    [No Abstract]   [Full Text] [Related]  

  • 18. In vivo/in vitro correlations for four differently dissolving ketorolac tablets.
    Gordon MS; Chowhan Z
    Biopharm Drug Dispos; 1996 Aug; 17(6):481-92. PubMed ID: 8866039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High pressure liquid chromatographic determination of sulfisoxazole in plasma.
    Peng GW; Gadalla MA; Chiou WL
    Res Commun Chem Pathol Pharmacol; 1977 Oct; 18(2):233-46. PubMed ID: 918345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.